Overview
Chorea caused by dopamine receptor antagonists (DRA-induced chorea) is a movement disorder characterized by involuntary, unpredictable movements resulting from the blockade of dopamine receptors, typically D2 receptors, predominantly found in the basal ganglia. This condition can arise as an adverse effect of antipsychotic medications, particularly those with high affinity for D2 receptors like haloperidol and droperidol. Clinically significant due to its potential to severely impact daily functioning and quality of syndrome, it predominantly affects individuals prescribed these medications for psychiatric disorders such as schizophrenia or severe behavioral disturbances. Recognizing and managing DRA-induced chorea is crucial in day-to-day practice to prevent prolonged disability and ensure appropriate treatment adjustments 45.Pathophysiology
DRA-induced chorea arises from the disruption of normal dopaminergic signaling within the basal ganglia circuitry, which is critical for motor control and coordination. Dopamine D2 receptors play a pivotal role in modulating the activity of the direct and indirect pathways in the striatum. When these receptors are antagonized, the balance between these pathways is disrupted, leading to abnormal neuronal firing patterns. Specifically, the blockade of D2 receptors in the striatum can enhance the activity of the indirect pathway, characterized by increased inhibition of the thalamus, and simultaneously reduce the facilitation of the direct pathway, resulting in dyskinetic movements 38. Additionally, interactions with other neurotransmitter systems, such as acetylcholine and opioids, further complicate the pathophysiology. For instance, acetylcholine dysregulation, as seen with muscarinic receptor blockade (e.g., by scopolamine), can exacerbate motor symptoms by interfering with normal striatal function and modulating pain pathways 2. These complex interactions highlight the multifaceted nature of chorea induced by dopamine receptor antagonists.Epidemiology
The incidence of DRA-induced chorea varies but is notably higher among patients treated with high-potency D2 receptor antagonists, particularly in elderly populations and those with pre-existing movement disorders like Parkinson's disease. Prevalence estimates are not consistently reported across studies, but it is recognized that younger individuals are less commonly affected compared to older adults. Geographic distribution does not show significant variations, but trends suggest an increased awareness and reporting in regions with advanced psychiatric care systems. Risk factors include higher doses of antipsychotics, prolonged use, and genetic predispositions to extrapyramidal symptoms 45.Clinical Presentation
The clinical presentation of DRA-induced chorea includes characteristic involuntary movements such as jerky, dance-like motions affecting the limbs, trunk, and face. Patients may also exhibit gait disturbances, speech difficulties (dysarthria), and in severe cases, cognitive impairment. Atypical presentations might include dystonia or akathisia, which can complicate the diagnosis. Red-flag features include rapid onset of symptoms following medication initiation, worsening despite dose reduction, and the presence of other neurological deficits that suggest an alternative diagnosis 4.Diagnosis
Diagnosing DRA-induced chorea involves a thorough clinical evaluation and exclusion of other causes of chorea. Key diagnostic criteria include:Differential Diagnosis:
Management
First-Line Treatment
Second-Line Treatment
Refractory Cases / Specialist Escalation
Contraindications:
Complications
Prognosis & Follow-Up
The prognosis for DRA-induced chorea is generally good with appropriate management, often leading to resolution or significant improvement within weeks to months. Prognostic indicators include early recognition and prompt reduction of the offending medication. Regular follow-up appointments every 2-4 weeks initially, tapering to monthly visits as symptoms stabilize, are recommended. Monitoring includes clinical assessments, medication review, and periodic neurological evaluations to ensure sustained improvement and prevent relapse 4.Special Populations
Key Recommendations
References
1 Han Y, Zhang JQ, Ji YW, Luan YW, Li SY, Geng HZ et al.. α4 nicotinic receptors on GABAergic neurons mediate a cholinergic analgesic circuit in the substantia nigra pars reticulata. Acta pharmacologica Sinica 2024. link 2 Perry ML, Pratt WE, Baldo BA. Overlapping striatal sites mediate scopolamine-induced feeding suppression and mu-opioid-mediated hyperphagia in the rat. Psychopharmacology 2014. link 3 Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. British journal of pharmacology 1998. link 4 Gilt S, Townsend BR, Nisly AE, Di Paola SG, Lentz AP, Luyten DR et al.. Droperidol vs. haloperidol for abdominal pain. The American journal of emergency medicine 2025. link 5 Townsend BR, Malka ST, Di Paola SG, Nisly AE, Gilbert BW. DRopEridol for Abdominal pain in the emergency department for Morphine Equivalent Reduction. The DREAMER study. The American journal of emergency medicine 2025. link 6 Strasser A, Wittmann HJ, Seifert R. Binding Kinetics and Pathways of Ligands to GPCRs. Trends in pharmacological sciences 2017. link 7 Kobrin KL, Arena DT, Heinrichs SC, Nguyen OH, Kaplan GB. Dopamine D1 receptor agonist treatment attenuates extinction of morphine conditioned place preference while increasing dendritic complexity in the nucleus accumbens core. Behavioural brain research 2017. link 8 Ponterio G, Tassone A, Sciamanna G, Riahi E, Vanni V, Bonsi P et al.. Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsal striatum. Neuropharmacology 2013. link 9 Zarrindast MR, Asgari-Afshar A, Sahebgharani M. Morphine-induced antinociception in the formalin test: sensitization and interactions with D1 and D2 dopamine receptors and nitric oxide agents. Behavioural pharmacology 2007. link 10 Laplante F, Nakagawasai O, Srivastava LK, Quirion R. Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005. link 11 Yamashita T, Isa T. Fulfenamic acid sensitive, Ca(2+)-dependent inward current induced by nicotinic acetylcholine receptors in dopamine neurons. Neuroscience research 2003. link00128-7) 12 Ghelardini C, Galeotti N, Bartolini A. Pharmacological identification of SM-21, the novel sigma(2) antagonist. Pharmacology, biochemistry, and behavior 2000. link00405-6) 13 Dourmap N, Clero E, Costentin J. Involvement of cholinergic neurons in the release of dopamine elicited by stimulation of mu-opioid receptors in striatum. Brain research 1997. link01319-4) 14 Sagan S, Josien H, Karoyan P, Brunissen A, Chassaing G, Lavielle S. Tachykinin NK-1 receptor probed with constrained analogues of substance P. Bioorganic & medicinal chemistry 1996. link00230-1) 15 Sakurada T, Yogo H, Manome Y, Tan-No K, Sakurada S, Yamada A et al.. Pharmacological characterisation of NK1 receptor antagonist, [D-Trp7]sendide, on behaviour elicited by substance P in the mouse. Naunyn-Schmiedeberg's archives of pharmacology 1994. link 16 Håkanson R, Wang ZY, Folkers K. Comparison of spantide II and CP-96,345 for blockade of tachykinin-evoked contractions of smooth muscle. Biochemical and biophysical research communications 1991. link91813-r) 17 Largent BL, Wikström H, Gundlach AL, Snyder SH. Structural determinants of sigma receptor affinity. Molecular pharmacology 1987. link